ArticleScientific reports2025
Fabrication of serum-based SERS-tailored 3D structures for thyroid cancer diagnosis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Early detection of thyroid cancer improves patient survival rate from 51.9% to 99.9%. Fine needle aspiration cytology is the primary method for diagnosing thyroid cancer; however, this method is associated with limitations, including diagnostic uncertainty and potential complications. Despite numerous studies to identify diagnostic biomarkers for thyroid cancer, none has been found to date. Therefore, new methods that do not rely on biomarkers are warranted to aid thyroid cancer diagnosis. Here, we suggest a novel approach using 3D gold nanoclusters to obtain Surface-enhanced Raman scattering (SERS) spectra using the serum samples of patients with thyroid cancer and normal individuals. Briefly, an evaporation-based 3D printing technique was employed to fabricate nanoclusters containing serum. SERS spectra were collected from 50 normal individuals and 50 patients with thyroid cancer. The spectra were then analysed using machine learning with 1D and 2D convolutional neural networks (CNNs) architecture. Notably, the 2D CNN exhibited superior performance for the classification of thyroid cancer cases, with sensitivity of 93.1% and specificity of 84.0%. Such findings suggest the potential use of metabolite analysis for the diagnosis of thyroid cancer without finding biomarkers. This SERS measurement approach using 3D nanoclusters may also be leveraged for the diagnosis of other diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.